A Biologic License Application has been submitted for isocabtagene maraleucel, a chimeric antigen receptor T-cell agent, as a treatment for adult patients with relapsed or refractory large B-cell lymphoma after a minimum of 2 prior therapies, Bristol-Myers Squibb, the manufacturer, reported in a press release.
Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.
Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.
During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of…
During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.
New trial results reveal BGB-16673’s promising safety and efficacy in treating relapsed CLL/SLL, showing significant antitumor activity across diverse patient profiles.
Theresa Medina, MD, discusses treatment with lifileucel in patients with advanced melanoma and the background of the C-144-01 study.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.
